1. TB VACCINES WORKING GROUP
Douglas Young
Stop TB Partners’ Forum
New Delhi
March 2004

2. live attenuated Mycobacterium bovis bacillus of Calmette and Guerin
BCG VACCINE
live attenuated Mycobacterium bovis
bacillus of Calmette and Guerin

3. BCG provides some useful level of protection against childhood TB
BCG provides little or no protection against adult pulmonary TB

4. X Primary tuberculosis, post-primary tuberculosis, and BCG disease
immune
response
disease
reactivation
reinfection
1° disease X
disease
BCG
infection
bacterial
load
few weeks
months/years/decades

5. 1. prevent establishment
Profile of improved tuberculosis vaccines
disease
disease
disease
bacterial
load
1. prevent establishment
of initial infection
2. prevent progression from latent infection
to active disease

6. attenuated mycobacteria
preclinical screening of 268 TB vaccine candidates
attenuated mycobacteria
(25)
recombinant vaccines
(29)
DNA vaccines
(43)
purified proteins
(114)
Ian Orme, Colorado State University

7. two new TB vaccine candidates are now in phase I clinical trials

8. Vaccine Expectations

9. partially protective vaccine + improved diagnostics + new drugs
clinical trials: opportunity for capacity strengthening

10. Vaccine Working Group Activities
provide an international forum for discussion of vaccine issues
economic case for TB vaccines
standardised regulatory requirements
trial site directory
immunological assays
BCG
interactive website